K
Kristine Pemberton
Researcher at AstraZeneca
Publications - 11
Citations - 2577
Kristine Pemberton is an academic researcher from AstraZeneca. The author has contributed to research in topics: Zibotentan & Placebo. The author has an hindex of 10, co-authored 11 publications receiving 2512 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Nick Thatcher,Alex R. Chang,Purvish M. Parikh,José Rodrigues Pereira,Tudor Ciuleanu,Joachim von Pawel,Sumitra Thongprasert,Eng Huat Tan,Kristine Pemberton,Venice Archer,Kevin H Carroll +10 more
TL;DR: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population, and there was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.
Journal ArticleDOI
Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
Karim Fizazi,Celestia S. Higano,Joel B. Nelson,Martin E. Gleave,Kurt Miller,Thomas Morris,F. E. Nathan,Stuart McIntosh,Kristine Pemberton,Judd W. Moul +9 more
TL;DR: Docetaxel plus zibotentan 10 mg/d did not result in a significant improvement in OS compared with docetaxe plus placebo in patients with metastatic CRPC, and no significant differences were observed on secondary end points.
Journal ArticleDOI
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
Joel B. Nelson,Karim Fizazi,Kurt Miller,Celestia S. Higano,Judd W. Moul,Hideyuki Akaza,Thomas Morris,Stuart McIntosh,Kristine Pemberton,Martin E. Gleave +9 more
TL;DR: This study aimed to determine whether the specific ETA receptor antagonist, zibotentan, prolonged overall survival (OS) in patients with castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain.
Journal ArticleDOI
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
Kurt Miller,Judd W. Moul,Martin E. Gleave,Karim Fizazi,Joel B. Nelson,Thomas Morris,F. E. Nathan,Stuart McIntosh,Kristine Pemberton,Celestia S. Higano +9 more
TL;DR: Owing to the absence of demonstrable survival benefits in the ENTHUSE clinical studies, zibotentan is no longer under investigation as a potential treatment for prostate cancer.
Journal ArticleDOI
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Gary T. Ferguson,Donald P. Tashkin,Tor Skärby,Carin Jorup,Kristina Sandin,Mike Greenwood,Kristine Pemberton,Frank Trudo +7 more
TL;DR: Budesonide/formoterol pMDI is an effective treatment option for reducing exacerbation rates in COPD patients with moderate-to-very-severe airflow limitation and history of exacerbations; safety data were consistent with its established profile.